{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:43:01Z","timestamp":1787726581539,"version":"build-2784847793"},"reference-count":126,"publisher":"The Endocrine Society","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Crinetics Pharmaceuticals, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The subset of pituitary adenomas with a heritable genetic basis is small but clinically striking. Somatotropinomas are amongst the most frequent pituitary adenoma subtypes encountered in this setting, with germline variants being enriched in familial acromegaly kindreds and people with a childhood or adolescent history of GH hypersecretion manifesting as pituitary gigantism.<\/jats:p>\n                  <jats:p>The genetic causes of familial acromegaly and pituitary gigantism include variants in established pituitary adenoma predisposition genes (AIP, especially, but also MEN1, CDKN1B, MAX, and PRKAR1A), X-linked acrogigantism due to Xq26.3 microduplications, and McCune-Albright syndrome due to postzygotic gain-of-function GNAS variants. Potential associations include variants in emerging pituitary adenoma predisposition genes, including NF1, PRKACB, PAM, and CHEK2. Given the potential for gene-specific therapeutic implications in these diseases, multimodal genetic testing arranged by experienced pituitary subspecialists and conducted in expert, clinically accredited laboratories is needed to fully evaluate the genetic basis of disease. Key investigations include next-generation sequencing, chromosome microarray, and droplet digital polymerase chain reaction.<\/jats:p>\n                  <jats:p>Exploratory research-based genetic testing may help uncover new genetic causes of familial acromegaly kindreds and pituitary gigantism in people with negative results on standard testing, benefiting those being tested as well as advancing our understanding of the heritable basis of somatotropinomas.<\/jats:p>","DOI":"10.1210\/clinem\/dgag151","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:36:59Z","timestamp":1775561819000},"page":"S13-S26","source":"Crossref","is-referenced-by-count":1,"title":["Genetics of familial acromegaly and pituitary gigantism"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0127-6482","authenticated-orcid":false,"given":"Sunita M C","family":"De Sousa","sequence":"first","affiliation":[{"name":"Adelaide Medical School, University of Adelaide , Adelaide 5000 ,","place":["Australia"]},{"name":"Endocrine and Metabolic Unit, Royal Adelaide Hospital , Adelaide 5000 ,","place":["Australia"]},{"name":"South Australian Adult Genetics Unit, Royal Adelaide Hospital , Adelaide 5000 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-2975","authenticated-orcid":false,"given":"Adrian F","family":"Daly","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Centre Hospitalier Universitaire de Li\u00e8ge, University of Li\u00e8ge , Li\u00e8ge 4000 ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"10","key":"2026060410075819700_dgag151-B1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1530\/ERC-17-0253","article-title":"Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge Acromegaly Survey (LAS) database","volume":"24","author":"Petrossians","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2026060410075819700_dgag151-B2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2026060410075819700_dgag151-B3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1530\/ERC-15-0320","article-title":"Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients","volume":"22","author":"Rostomyan","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"2026060410075819700_dgag151-B4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41574-018-0114-1","article-title":"The causes and consequences of pituitary gigantism","volume":"14","author":"Beckers","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"Suppl","key":"2026060410075819700_dgag151-B5","first-page":"S202","article-title":"Ueber heretid\u00e4re akromegalie","volume":"32","author":"Schwoner","year":"1897","journal-title":"Zeitsch f klin Med"},{"key":"2026060410075819700_dgag151-B6","volume-title":"Die Akromegalie, von Dr. Maximilian Sternberg","author":"Sternberg","year":"1897"},{"issue":"9","key":"2026060410075819700_dgag151-B7","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1210\/jc.2005-2671","article-title":"Clinical characterization of familial isolated pituitary adenomas","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060410075819700_dgag151-B8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/er.2012-1013","article-title":"Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene","volume":"34","author":"Beckers","year":"2013","journal-title":"Endocr Rev"},{"issue":"9","key":"2026060410075819700_dgag151-B9","doi-asserted-by":"crossref","first-page":"E1242","DOI":"10.1210\/jc.2015-1869","article-title":"Landscape of familial isolated and young-onset pituitary adenomas: prospective diagnosis in AIP mutation carriers","volume":"100","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026060410075819700_dgag151-B10","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical biology of the pituitary adenoma","volume":"43","author":"Melmed","year":"2022","journal-title":"Endocr Rev"},{"key":"2026060410075819700_dgag151-B11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/B978-0-323-99899-4.00014-7","volume-title":"The Pituitary","author":"Daly","year":"2022"},{"issue":"6","key":"2026060410075819700_dgag151-B12","doi-asserted-by":"crossref","first-page":"e2247","DOI":"10.1210\/clinem\/dgaa040","article-title":"Significant benefits of AIP testing and clinical screening in familial isolated and young-onset pituitary tumors","volume":"105","author":"Marques","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026060410075819700_dgag151-B13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S2213-8587(25)00119-6","article-title":"Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice","volume":"13","author":"Brandi","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"17","key":"2026060410075819700_dgag151-B14","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-24-3860","article-title":"Updated recommendations for pediatric surveillance in hereditary endocrine neoplasia syndromes: multiple endocrine neoplasias, hyperparathyroidism-jaw tumor syndrome, and Carney Complex","volume":"31","author":"Wasserman","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2026060410075819700_dgag151-B15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41574-024-01024-5","article-title":"International consensus statement on the diagnosis and management of phaeochromocytoma and paraganglioma in children and adolescents","volume":"20","author":"Casey","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"2026060410075819700_dgag151-B16","author":"Stratakis"},{"key":"2026060410075819700_dgag151-B17","author":"Szymczuk"},{"issue":"2","key":"2026060410075819700_dgag151-B18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/JOE-11-0054","article-title":"AIP and its interacting partners","volume":"210","author":"Trivellin","year":"2011","journal-title":"J Endocrinol"},{"issue":"6","key":"2026060410075819700_dgag151-B19","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1210\/jc.2007-2611","article-title":"The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas","volume":"93","author":"Leontiou","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"5777","key":"2026060410075819700_dgag151-B20","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1126\/science.1126100","article-title":"Pituitary adenoma predisposition caused by germline mutations in the AIP gene","volume":"312","author":"Vierimaa","year":"2006","journal-title":"Science"},{"issue":"5","key":"2026060410075819700_dgag151-B21","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.celrep.2019.04.014","article-title":"Aryl hydrocarbon receptor interacting protein maintains germinal center B cells through suppression of BCL6 degradation","volume":"27","author":"Sun","year":"2019","journal-title":"Cell Rep"},{"issue":"11","key":"2026060410075819700_dgag151-B22","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/s41416-022-01762-1","article-title":"Aryl-hydrocarbon receptor-interacting protein regulates tumorigenic and metastatic properties of colorectal cancer cells driving liver metastasis","volume":"126","author":"Sol\u00eds-Fern\u00e1ndez","year":"2022","journal-title":"Br J Cancer"},{"issue":"12","key":"2026060410075819700_dgag151-B23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053339","article-title":"Structure of the TPR domain of AIP: lack of client protein interaction with the C-terminal \u03b1-7 helix of the TPR domain of AIP is sufficient for pituitary adenoma predisposition","volume":"7","author":"Morgan","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"2026060410075819700_dgag151-B24","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2016-1307","article-title":"Rapid proteasomal degradation of mutant proteins is the primary mechanism leading to tumorigenesis in patients with missense AIP mutations","volume":"101","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060410075819700_dgag151-B25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1677\/ERC-09-0094","article-title":"Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications","volume":"16","author":"Jaffrain-Rea","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2026060410075819700_dgag151-B26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/ERC-15-0205","article-title":"cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors","volume":"23","author":"Bolger","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2026060410075819700_dgag151-B27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1530\/ERC-13-0043","article-title":"AIP regulates cAMP signalling and growth hormone secretion in GH3 cells","volume":"20","author":"Formosa","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"9","key":"2026060410075819700_dgag151-B28","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/onc.2014.50","article-title":"AIP inactivation leads to pituitary tumorigenesis through defective Galphai-cAMP signaling","volume":"34","author":"Tuominen","year":"2015","journal-title":"Oncogene"},{"issue":"12","key":"2026060410075819700_dgag151-B29","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/ijc.33268","article-title":"miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance","volume":"147","author":"Bogner","year":"2020","journal-title":"Int J Cancer"},{"issue":"2","key":"2026060410075819700_dgag151-B30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117107","article-title":"Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas","volume":"10","author":"Denes","year":"2015","journal-title":"PLoS One"},{"issue":"45","key":"2026060410075819700_dgag151-B31","doi-asserted-by":"crossref","first-page":"6354","DOI":"10.1038\/s41388-021-02009-8","article-title":"RET signalling provides tumorigenic mechanism and tissue specificity for AIP-related somatotrophinomas","volume":"40","author":"Garcia-Rendueles","year":"2021","journal-title":"Oncogene"},{"issue":"5","key":"2026060410075819700_dgag151-B32","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1210\/jc.2006-2513","article-title":"Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families","volume":"92","author":"Daly","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026060410075819700_dgag151-B33","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2026060410075819700_dgag151-B34","article-title":"OR25-07 a novel and severe multisystem metabolic disease due to homozygous AIP variants","volume":"9","author":"Korbonits","year":"2025","journal-title":"J Endocr Soc"},{"issue":"5","key":"2026060410075819700_dgag151-B35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1399-0004.2010.01406.x","article-title":"The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes","volume":"78","author":"Stratakis","year":"2010","journal-title":"Clin Genet"},{"issue":"25","key":"2026060410075819700_dgag151-B36","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa1408028","article-title":"Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation","volume":"371","author":"Trivellin","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"2026060410075819700_dgag151-B37","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ajhg.2022.02.002","article-title":"Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism","volume":"109","author":"Franke","year":"2022","journal-title":"Am J Hum Genet"},{"issue":"3","key":"2026060410075819700_dgag151-B38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/ERC-15-0038","article-title":"X-linked acrogigantism syndrome: clinical profile and therapeutic responses","volume":"22","author":"Beckers","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2026060410075819700_dgag151-B39","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1038\/s41467-020-18500-x","article-title":"GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq\/11","volume":"11","author":"Abboud","year":"2020","journal-title":"Nat Commun"},{"key":"2026060410075819700_dgag151-B40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.116013","article-title":"Basal interaction of the orphan receptor GPR101 with arrestins leads to constitutive internalization","volume":"220","author":"Abboud","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"2026060410075819700_dgag151-B41","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1210\/endrev\/bnae014","article-title":"The genetic pathophysiology and clinical management of the TADopathy, X-linked acrogigantism","volume":"45","author":"Daly","year":"2024","journal-title":"Endocr Rev"},{"issue":"3","key":"2026060410075819700_dgag151-B42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1530\/ERC-15-0478","article-title":"GHRH excess and blockade in X-LAG syndrome","volume":"23","author":"Daly","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2026060410075819700_dgag151-B43","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40478-016-0328-1","article-title":"Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study","volume":"4","author":"Iacovazzo","year":"2016","journal-title":"Acta Neuropathol Commun"},{"issue":"12","key":"2026060410075819700_dgag151-B44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005640","article-title":"Minor loops in major folds: enhancer-promoter looping, chromatin restructuring, and their association with transcriptional regulation and disease","volume":"11","author":"Matharu","year":"2015","journal-title":"PLoS Genet"},{"key":"2026060410075819700_dgag151-B45","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2023.102622","article-title":"TADs: dynamic structures to create stable regulatory functions","volume":"81","author":"da Costa-Nunes","year":"2023","journal-title":"Curr Opin Struct Biol"},{"issue":"10","key":"2026060410075819700_dgag151-B46","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1210\/jc.2019-00817","article-title":"Familial X-linked acrogigantism: postnatal outcomes and tumor pathology in a prenatally diagnosed infant and his mother","volume":"104","author":"Wise-Oringer","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060410075819700_dgag151-B47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1530\/ERC-16-0082","article-title":"Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects","volume":"23","author":"Daly","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2026060410075819700_dgag151-B48","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1345363","article-title":"Case report: management of pediatric gigantism caused by the TADopathy, X-linked acrogigantism","volume":"15","author":"Caruso","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026060410075819700_dgag151-B49","article-title":"Effective long-term pediatric pegvisomant monotherapy to final height in X-linked acrogigantism","volume":"1","author":"Burren","year":"2023","journal-title":"JCEM Case Rep"},{"issue":"5311","key":"2026060410075819700_dgag151-B50","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia-type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science"},{"issue":"9","key":"2026060410075819700_dgag151-B51","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1210\/JC.2015-2015","article-title":"Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 study group (DMSG)","volume":"100","author":"de Laat","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060410075819700_dgag151-B52","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-12-0763","article-title":"Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don\u2019t forget MEN1 genetic analysis","volume":"168","author":"Cuny","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060410075819700_dgag151-B53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"42","key":"2026060410075819700_dgag151-B54","doi-asserted-by":"crossref","first-page":"15558","DOI":"10.1073\/pnas.0603877103","article-title":"Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans","volume":"103","author":"Pellegata","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2026060410075819700_dgag151-B55","doi-asserted-by":"crossref","first-page":"e1482","DOI":"10.1210\/clinem\/dgae055","article-title":"Beyond MEN1, when to think about MEN4? Retrospective study on 5600 patients in the French population and literature review","volume":"109","author":"Chevalier","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060410075819700_dgag151-B56","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0174","article-title":"Germline CDKN1B variant type and site are associated with phenotype in MEN4","volume":"30","author":"Halperin","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2026060410075819700_dgag151-B57","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s12020-023-03497-2","article-title":"Multiple endocrine neoplasia type 4 (MEN4): a thorough update on the latest and least known men syndrome","volume":"82","author":"Ruggeri","year":"2023","journal-title":"Endocrine"},{"issue":"1","key":"2026060410075819700_dgag151-B58","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3803\/EnM.2024.2074","article-title":"Pituitary neuroendocrine tumors in multiple endocrine neoplasia","volume":"40","author":"Chin","year":"2025","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"8","key":"2026060410075819700_dgag151-B59","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1210\/clinem\/dgac162","article-title":"MEN4, the MEN1 mimicker: a case series of three phenotypically heterogenous patients with unique CDKN1B mutations","volume":"107","author":"Seabrook","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026060410075819700_dgag151-B60","article-title":"A pituitary macroadenoma cosecreting prolactin and growth hormone in a patient with multiple endocrine neoplasia type 4","volume":"3","author":"Green","year":"2025","journal-title":"JCEM Case Rep"},{"issue":"3","key":"2026060410075819700_dgag151-B61","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1530\/ERC-11-0362","article-title":"Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds","volume":"19","author":"Tichomirowa","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2026060410075819700_dgag151-B62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12020-015-0540-y","article-title":"Early onset acromegaly associated with a novel deletion in CDKN1B 5\u2032UTR region","volume":"49","author":"Sambugaro","year":"2015","journal-title":"Endocrine"},{"issue":"4998","key":"2026060410075819700_dgag151-B63","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.2006410","article-title":"Max: a Helix-loop-Helix zipper protein that forms a sequence-specific DNA-binding Complex with myc","volume":"251","author":"Blackwood","year":"1991","journal-title":"Science"},{"key":"2026060410075819700_dgag151-B64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116194","article-title":"MYC the oncogene from hell: novel opportunities for cancer therapy","volume":"267","author":"Papadimitropoulou","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"7","key":"2026060410075819700_dgag151-B65","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/MCB.15.7.3470","article-title":"The nerve growth factor-responsive PC12 cell line does not express the myc dimerization partner Max","volume":"15","author":"Hopewell","year":"1995","journal-title":"Mol Cell Biol"},{"issue":"10","key":"2026060410075819700_dgag151-B66","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1078-0432.CCR-12-0160","article-title":"MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma","volume":"18","author":"Burnichon","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2026060410075819700_dgag151-B67","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ng.861","article-title":"Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma","volume":"43","author":"Comino-M\u00e9ndez","year":"2011","journal-title":"Nat Genet"},{"issue":"6","key":"2026060410075819700_dgag151-B68","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11102-025-01607-z","article-title":"Loss of heterozygosity and absence of MAX immunostaining in a prolactinoma associated with multiple endocrine neoplasia type 5 (MEN5)","volume":"28","author":"Delemer","year":"2025","journal-title":"Pituitary"},{"issue":"4","key":"2026060410075819700_dgag151-B69","doi-asserted-by":"crossref","first-page":"e1163","DOI":"10.1210\/clinem\/dgaa957","article-title":"Multiple endocrine tumors associated with germline MAX mutations: multiple endocrine neoplasia type 5?","volume":"106","author":"Seabrook","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026060410075819700_dgag151-B70","first-page":"e453","article-title":"Case report of bilateral pheochromocytomas due to a novel max mutation in a patient known to have a pituitary prolactinoma","volume":"4","author":"Kobza","year":"2018","journal-title":"AACE Clin Case Rep"},{"issue":"5","key":"2026060410075819700_dgag151-B71","doi-asserted-by":"crossref","first-page":"L37","DOI":"10.1530\/ERC-18-0065","article-title":"Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions","volume":"25","author":"Daly","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"2026060410075819700_dgag151-B72","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1530\/ERC-22-0157","article-title":"Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours","volume":"29","author":"Loughrey","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2026060410075819700_dgag151-B73","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s12020-025-04186-y","article-title":"Expanding the phenotype of multiple endocrine neoplasia type 5 (MEN5): pituitary gigantism, myelolipoma and familial pheochromocytoma due to a germline pathogenic MAX variant","volume":"88","author":"Haider","year":"2025","journal-title":"Endocrine"},{"issue":"1","key":"2026060410075819700_dgag151-B74","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/79238","article-title":"Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex","volume":"26","author":"Kirschner","year":"2000","journal-title":"Nat Genet"},{"issue":"10","key":"2026060410075819700_dgag151-B75","first-page":"3860","article-title":"Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the \u201ccomplex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas\u201d (Carney complex)","volume":"85","author":"Pack","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060410075819700_dgag151-B76","doi-asserted-by":"crossref","first-page":"e694","DOI":"10.1210\/clinem\/dgae253","article-title":"The spectrum of GH excess in Carney complex and genotype-phenotype correlations","volume":"110","author":"Tatsi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060410075819700_dgag151-B77","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1210\/clinem\/dgaa002","article-title":"Frequency and incidence of carney complex manifestations: a prospective multicenter study with a three-year follow-up","volume":"105","author":"Espiard","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060410075819700_dgag151-B78","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1530\/EJE-20-1120","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: Carney complex: clinical and genetic update 20 years after the identification of the CNC1 (PRKAR1A) gene","volume":"184","author":"Bouys","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026060410075819700_dgag151-B79","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1210\/jc.2008-2333","article-title":"Mutations in regulatory subunit type 1A of cyclic adenosine 5\u2032-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes","volume":"94","author":"Bertherat","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026060410075819700_dgag151-B80","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMc1309730","article-title":"PRKACB and Carney complex","volume":"370","author":"Forlino","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"2026060410075819700_dgag151-B81","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1530\/ERC-20-0309","article-title":"PRKACB variants in skeletal disease or adrenocortical hyperplasia: effects on protein kinase A","volume":"27","author":"Espiard","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2026060410075819700_dgag151-B82","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1750-1172-3-12","article-title":"McCune-Albright syndrome","volume":"3","author":"Dumitrescu","year":"2008","journal-title":"Orphanet J Rare Dis"},{"issue":"24","key":"2026060410075819700_dgag151-B83","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM199112123252403","article-title":"Activating mutations of the stimulatory G protein in the McCune\u2013Albright syndrome","volume":"325","author":"Weinstein","year":"1991","journal-title":"N Engl J Med"},{"issue":"6","key":"2026060410075819700_dgag151-B84","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1210\/jc.2013-3826","article-title":"Acromegaly and McCune-Albright syndrome","volume":"99","author":"Salenave","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026060410075819700_dgag151-B85","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1210\/jc.2001-012022","article-title":"Characterization of Gsp-mediated growth hormone excess in the context of McCune-Albright syndrome","volume":"87","author":"Akintoye","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060410075819700_dgag151-B86","doi-asserted-by":"crossref","first-page":"E126","DOI":"10.1210\/jc.2012-2111","article-title":"Optic neuropathy in McCune\u2013Albright syndrome: effects of early diagnosis and treatment of growth hormone excess","volume":"98","author":"Boyce","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026060410075819700_dgag151-B87","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1210\/jc.2005-2661","article-title":"Pegvisomant for the treatment of GSP-mediated growth hormone excess in patients with McCune\u2013Albright syndrome","volume":"91","author":"Akintoye","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026060410075819700_dgag151-B88","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1210\/jc.2012-1274","article-title":"Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune\u2013Albright syndrome","volume":"97","author":"Vortmeyer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026060410075819700_dgag151-B89","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/a-0661-0341","article-title":"The 3PAs: an update on the association of pheochromocytomas, paragangliomas, and pituitary tumors","volume":"51","author":"Xekouki","year":"2019","journal-title":"Horm Metab Res"},{"issue":"5","key":"2026060410075819700_dgag151-B90","doi-asserted-by":"crossref","first-page":"E710","DOI":"10.1210\/jc.2014-4297","article-title":"Pituitary adenoma with paraganglioma\/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice","volume":"100","author":"Xekouki","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060410075819700_dgag151-B91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0004.2006.00639.x","article-title":"Neurofibromin: a general outlook","volume":"70","author":"Trov\u00f3-Marqui","year":"2006","journal-title":"Clin Genet"},{"issue":"8","key":"2026060410075819700_dgag151-B92","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3390\/jcm11082168","article-title":"Neurofibromatosis type 1 has a wide spectrum of growth hormone excess","volume":"11","author":"Hannah-Shmouni","year":"2022","journal-title":"J Clin Med"},{"issue":"4","key":"2026060410075819700_dgag151-B93","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3171\/jns.1994.81.4.0595","article-title":"Optic pathway glioma infiltrating into somatostatinergic pathways in a young boy with gigantism. Case report","volume":"81","author":"Manski","year":"1994","journal-title":"J Neurosurg"},{"key":"2026060410075819700_dgag151-B94","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1483305","article-title":"Association of pituitary neuroendocrine tumors and neurofibromatosis type 1: assessing causation versus coincidence. Case report","volume":"16","author":"Aguilar-Soto","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026060410075819700_dgag151-B95","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/humu.10305","article-title":"Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors","volume":"23","author":"Upadhyaya","year":"2004","journal-title":"Hum Mutat"},{"issue":"1","key":"2026060410075819700_dgag151-B96","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1677\/ERC-08-0142","article-title":"Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review","volume":"16","author":"Dworakowska","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2026060410075819700_dgag151-B97","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ejendo\/lvaf113","article-title":"Growth hormone excess in children with neurofibromatosis and optic pathway glioma, an underdiagnosed condition: experience with long-acting treatment","volume":"193","author":"Casano-Sancho","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026060410075819700_dgag151-B98","doi-asserted-by":"crossref","first-page":"T63","DOI":"10.1530\/JME-15-0266","article-title":"60 YEARS OF POMC: from POMC and \u03b1-MSH to PAM, molecular oxygen, copper, and vitamin C","volume":"56","author":"Kumar","year":"2016","journal-title":"J Mol Endocrinol"},{"issue":"3","key":"2026060410075819700_dgag151-B99","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0022-3476(78)81170-6","article-title":"Acromegalic gigantism and tuberous sclerosis","volume":"93","author":"Hoffman","year":"1978","journal-title":"J Pediatr"},{"issue":"5","key":"2026060410075819700_dgag151-B100","first-page":"1477","article-title":"Subependymal astrocytic hamartomas in the Eker rat model of tuberous sclerosis","volume":"151","author":"Yeung","year":"1997","journal-title":"Am J Pathol"},{"key":"2026060410075819700_dgag151-B101","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1166076","article-title":"Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion","volume":"14","author":"Trivellin","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026060410075819700_dgag151-B102","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1305606","article-title":"PAM variants in patients with thyrotrophinomas, cyclical Cushing's disease and prolactinomas","volume":"14","author":"De Sousa","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026060410075819700_dgag151-B103","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1210\/clinem\/dgae510","article-title":"Deficiency of peptidylglycine-alpha-amidating monooxygenase, a cause of sarcopenic diabetes mellitus","volume":"110","author":"Giontella","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026060410075819700_dgag151-B104","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2023.100870","article-title":"Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Hanson","year":"2023","journal-title":"Genet Med"},{"issue":"11","key":"2026060410075819700_dgag151-B105","first-page":"2720","article-title":"Increased prevalence of germline pathogenic CHEK2 variants in individuals with pituitary adenomas","volume":"109","author":"De Sousa","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060410075819700_dgag151-B106","first-page":"85","article-title":"Recurrent acromegaly in a patient with a CHEK2 mutation","volume":"8","author":"Perosevic","year":"2021","journal-title":"AACE Clin Case Rep"},{"issue":"6236","key":"2026060410075819700_dgag151-B107","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/340692a0","article-title":"GTPase-inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours","volume":"340","author":"Landis","year":"1989","journal-title":"Nature"},{"issue":"2","key":"2026060410075819700_dgag151-B108","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ejendo\/lvae013","article-title":"KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomas","volume":"190","author":"Chasseloup","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060410075819700_dgag151-B109","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12902-020-0495-8","article-title":"A putative role for the aryl hydrocarbon receptor (AHR) gene in a patient with cyclical Cushing's disease","volume":"20","author":"De Sousa","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"2026060410075819700_dgag151-B110","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0272","article-title":"From bench to bedside in the sella: translational developments in pituitary tumour genetics","volume":"32","author":"De Sousa","year":"2025","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2026060410075819700_dgag151-B111","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","article-title":"Consensus on acromegaly therapeutic outcomes: an update","volume":"21","author":"Melmed","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2026060410075819700_dgag151-B112","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1530\/EJE-16-0944","article-title":"Germline variants in familial pituitary tumour syndrome genes are common in young patients and families with additional endocrine tumours","volume":"176","author":"De Sousa","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026060410075819700_dgag151-B113","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1093\/ejendo\/lvaf100","article-title":"Revised European Society of Endocrinology clinical practice guideline for the management of aggressive pituitary tumours and pituitary carcinomas","volume":"192","author":"Raverot","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060410075819700_dgag151-B114","first-page":"17","article-title":"Genetic testing in endocrinology","volume":"39","author":"De Sousa","year":"2018","journal-title":"Clin Biochem Rev"},{"issue":"5","key":"2026060410075819700_dgag151-B115","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","article-title":"Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a Pituitary Society statement","volume":"20","author":"Casanueva","year":"2017","journal-title":"Pituitary"},{"issue":"5","key":"2026060410075819700_dgag151-B116","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"2","key":"2026060410075819700_dgag151-B117","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/endrev\/bnaa031","article-title":"Multiple endocrine neoplasia type 1: latest insights","volume":"42","author":"Brandi","year":"2021","journal-title":"Endocr Rev"},{"issue":"4","key":"2026060410075819700_dgag151-B118","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11102-025-01559-4","article-title":"Non-penetrant Xq26.3 duplication involving the invariant TAD border: clinical evidence for the VGLL1 region as the GPR101 pituitary enhancer of X-linked acrogigantism","volume":"28","author":"Hilditch","year":"2025","journal-title":"Pituitary"},{"issue":"1","key":"2026060410075819700_dgag151-B119","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41525-025-00548-7","article-title":"Distinguishing benign from pathogenic duplications involving GPR101 and VGLL1-adjacent enhancers in the clinical setting with the bioinformatic tool POSTRE","volume":"11","author":"Trivellin","year":"2026","journal-title":"NPJ Genom Med"},{"issue":"1","key":"2026060410075819700_dgag151-B120","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13073-024-01378-5","article-title":"Chromatin conformation capture in the clinic: 4C-seq\/HiC distinguishes pathogenic from neutral duplications at the GPR101 locus","volume":"16","author":"Daly","year":"2024","journal-title":"Genome Med"},{"issue":"3","key":"2026060410075819700_dgag151-B121","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-22-0291","article-title":"Pituitary tumours: molecular and genetic aspects","volume":"257","author":"De Sousa","year":"2023","journal-title":"J Endocrinol"},{"issue":"5","key":"2026060410075819700_dgag151-B122","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1210\/jc.2003-031225","article-title":"Activating Gsalpha mutations: analysis of 113 patients with signs of McCune\u2013Albright syndrome\u2014a European Collaborative study","volume":"89","author":"Lumbroso","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060410075819700_dgag151-B123","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jpeds.2018.09.070","article-title":"Using digital droplet polymerase chain reaction to detect the mosaic GNAS mutations in whole blood DNA or circulating cell-free DNA in fibrous dysplasia and McCune-Albright syndrome","volume":"205","author":"Romanet","year":"2019","journal-title":"J Pediatr"},{"issue":"10","key":"2026060410075819700_dgag151-B124","doi-asserted-by":"crossref","first-page":"E2029","DOI":"10.1210\/jc.2014-1291","article-title":"McCune\u2013Albright syndrome: a detailed pathological and genetic analysis of disease effects in an adult patient","volume":"99","author":"Vasilev","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026060410075819700_dgag151-B125","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2015-4366","article-title":"Somatic GPR101 duplication causing X-linked acrogigantism (XLAG)-diagnosis and management","volume":"101","author":"Rodd","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060410075819700_dgag151-B126","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1210\/jc.2013-2868","article-title":"Clinical experience in the screening and management of a large kindred with familial isolated pituitary adenoma due to an aryl hydrocarbon receptor interacting protein (AIP) mutation","volume":"99","author":"Williams","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag151\/67993763\/dgag151.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/Supplement_1\/S13\/67993763\/dgag151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/Supplement_1\/S13\/67993763\/dgag151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:08:21Z","timestamp":1780582101000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/Supplement_1\/S13\/8644427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":126,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,4,8]]},"published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag151","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,8]]}}}